Results 71 to 80 of about 3,067,072 (318)
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background An internal tandem duplication in the gene encoding Fms‐like tyrosine kinase 3 (FLT3‐ITD) is associated with high relapse risk and poor prognosis in acute myeloid leukemia (AML) and plays a crucial role in treatment decisions. Measurable residual disease (MRD) analysis of FLT3‐ITD during and after treatment has shown prognostic ...
Sofie Johansson Alm +11 more
wiley +1 more source
Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses
Frontiers in ImmunologyBiologics play a positive and effective role in the treatment of immune-related dermatoses. However, many other immune-related diseases have also manifested along with biologics treatment.
Yaxin Zhang, Guan Jiang
semanticscholar +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta +6 more
wiley +1 more source
JAK-STAT6 inhibitors decrease IL-13-induced eotaxin-3 expression in esophageal fibroblasts.
, 2016 IL-13-induced (a) STAT6 phosphorylation, (b) eotaxin-3 mRNA, and (c) eotaxin-3 protein expression are decreased in esophageal fibroblasts, following treatment with JAK-STAT6 inhibitors (AS1517499 and leflunomide).
Xi Zhang (83736) +9 more
core +1 more source
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Objective To compare the efficacy and safety of roxarestat versus recombinant human erythropoietin (rhEPO) in the management of renal anemia in patients undergoing maintenance hemodialysis. Methods This was a prospective, open‐label, randomized controlled trial.
Lingling Chen, Junjie Zhu, Qiaonan Ge
wiley +1 more source
JAK-STAT6 inhibitors decrease IL-13-induced eotaxin-3 expression in esophageal epithelial cells.
, 2016 IL-13-induced (a) STAT6 phosphorylation, (b) eotaxin-3 mRNA, and (c) eotaxin-3 protein expression are decreased in esophageal epithelial cells, following treatment with JAK-STAT6 inhibitors (AS1517499 and leflunomide).
Xi Zhang (83736) +9 more
core +1 more source
Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
, 2022 Systemic lupus erythematosus (SLE) is a chronic, multifactorial autoimmune disease with complex pathogenesis characterized by the imbalance of pro-inflammatory and anti-inflammatory cytokines.
Buliga-Finis, Oana Nicoleta +13 more
core +1 more source
Dietary Protein Intake and Peritoneal Protein Losses in Peritoneal Dialysis Patients
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Introduction Peritoneal dialysis (PD) patients lose protein in their waste dialysate, potentially increasing their risk for malnutrition. We wished to determine whether there was any association between losses and dietary protein intake (DPI). Methods DPI was assessed from 24‐h dietary recall using Nutrics software.
Haalah Shaaker, Andrew Davenport
wiley +1 more source
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Introduction This study investigated the safety and efficacy of single‐needle Rheocarna therapy for chronic limb‐threatening ischemia (CLTI) with wounds. Methods Six patients with CLTI involving ulcers unresponsive to revascularization underwent single‐needle Rheocarna treatment.
Yasutaka Yamauchi +9 more
wiley +1 more source
JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis
Leukemia, 2021 We analyzed reports on safety and efficacy of JAK-inhibitors in patients with coronavirus infectious disease-2019 (COVID-19) published between January 1st and March 6th 2021 using the Newcastle-Ottawa and Jadad scales for quality assessment.
Chong-xiang Chen +5 more
semanticscholar +1 more source